ADIAL PHARMACEUTICALS Files 8-K on Equity Incentive Plan
Ticker: ADIL · Form: 8-K · Filed: 2026-04-09T17:00:08-04:00
Sentiment: neutral
Topics: executive-compensation, equity-incentive-plan, filing
TL;DR
ADIAL PHARMACEUTICALS updated its equity incentive plan, filing an 8-K on 4/9/2026.
AI Summary
ADIAL PHARMACEUTICALS, INC. filed an 8-K on April 9, 2026, reporting changes in officers and compensatory arrangements. Specifically, the company entered into a Form of Restricted Stock Award Agreement under its 2017 Equity Incentive Plan.
Why It Matters
This filing indicates potential changes in executive compensation and equity grants, which could impact shareholder value and employee incentives.
Risk Assessment
Risk Level: low — The filing is a routine disclosure regarding executive compensation and equity plans, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- ADIAL PHARMACEUTICALS, INC. (company) — Filer of the 8-K
- 2017 Equity Incentive Plan (plan) — Subject of the Restricted Stock Award Agreement
FAQ
What specific compensatory arrangements were made under the 2017 Equity Incentive Plan?
The filing indicates a 'FORM OF RESTRICTED STOCK AWARD AGREEMENT UNDER 2017 EQUITY INCENTIVE PLAN' was filed as an exhibit, suggesting new or updated stock awards.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 9, 2026.
What is the CIK number for ADIAL PHARMACEUTICALS, INC.?
The CIK number for ADIAL PHARMACEUTICALS, INC. is 0001513525.
What are the business and mailing addresses for ADIAL PHARMACEUTICALS, INC.?
Both the business and mailing addresses are listed as 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901.
Which items of Form 8-K are addressed in this filing?
This filing addresses Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits).
From the Filing
EDGAR Filing Documents for 0001213900-26-042057 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001213900-26-042057 Filing Date 2026-04-09 Accepted 2026-04-09 17:00:08 Documents 12 Period of Report 2026-04-07 Items Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 CURRENT REPORT ea0285772-8k_adial.htm iXBRL 8-K 40738 2 FORM OF RESTRICTED STOCK AWARD AGREEMENT UNDER 2017 EQUITY INCENTIVE PLAN ea028577201ex10-1.htm EX-10.1 62502 Complete submission text file 0001213900-26-042057.txt 280179 Data Files Seq Description Document Type Size 3 XBRL SCHEMA FILE adil-20260407.xsd EX-101.SCH 3005 4 XBRL LABEL FILE adil-20260407_lab.xml EX-101.LAB 34239 5 XBRL PRESENTATION FILE adil-20260407_pre.xml EX-101.PRE 22352 15 EXTRACTED XBRL INSTANCE DOCUMENT ea0285772-8k_adial_htm.xml XML 3189 Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800 ADIAL PHARMACEUTICALS, INC. (Filer) CIK : 0001513525 (see all company filings) EIN. : 800667150 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 26852345 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)